Lupin has received final approval for its Hydroxychloroquine Sulfate Tablets USP, 200 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Concordia Pharmaceuticals, Inc.'s Plaquenil Tablets, 200 mg.
Lupin's Hydroxychloroquine Sulfate Tablets USP, 200 mg is the generic version of Concordia Pharmaceuticals, Inc.'s Plaquenil Tablets, 200 mg. It is indicated for the treatment of uncomplicated malaria due to P. falciparum, P. malariae, P. ovale, and P. vivax and the prophylaxis of malaria in geographic areas where chloroquine resistance is not reported. It is also indicated for the treatment of chronic discoid lupus erythematosus and systemic lupus erythematosus in adults and the treatment of acute and chronic rheumatoid arthritis in adults.
Hydroxychloroquine Sulfate Tablets USP, 200 mg had annual sales of approximately $215.3 million in the US (IQVIA MAT April 2018).
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
